Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanoValent Pharmaceutical Partners with Children's Hospital of Los Angeles

Abstract:
Nanovalent Pharmaceuticals of Bozeman, Montana has entered into a collaboration with oncology researchers at Children's Hospital of Los Angeles. The partnership will focus on generating efficacy data in murine models of Ewing's Sarcoma and Acute Lymphoblastic Leukemia utilizing Nanovalent's drug candidates NANO-EW and NANO-ALL.

NanoValent Pharmaceutical Partners with Children's Hospital of Los Angeles

Bozeman, MT | Posted on December 1st, 2007

NANO-EW, NanoValent's lead cancer drug candidate is a transferrin surface targeted nanoparticle loaded with the chemotherapeutic SN38. The Company's primary indication is Ewing's Sarcoma. However, the firm intends to expand development efforts to include non-small cell lung cancer and hepatocellular carcinoma.

NANO-ALL is a transferrin surface targeted nanoparticle delivering siRNA fragments intended to silence gene sequences specific to acute lymphoblastic leukemia.

The Company is developing therapeutics against pediatric and adult cancers using proprietary polymerized liposomal nanoparticle (PLN) drug delivery technology.

####

About Nanovalent Pharmaceuticals
NanoValent Pharmaceuticals, Inc. (NVP) is a Delaware C-corporation commercializing a drug delivery platform that differentiates itself from other particle delivery systems through several key features. NanoValent particles are highly robust, customizable, stable, cheap, and easy to manufacture. The technology is capable of delivering a wide array of drug molecules or drug cocktails using multiple tissue targeting ligands. While other firms have successfully used targeted particles to deliver pharmaceuticals, few competitors have a payload specific custom offering with the flexibility to target using any surface ligand and deliver virtually any drug or biological payload. The platform product and manufacturing protocols are complete and the company has secured patents along with significant grant funding. The Companyís strategy is to develop several internal delivery programs, while leveraging the versatility of the platform technology providing custom drug delivery solutions to academic and private drug development programs. Internal development efforts are focused on vaccines, cancer therapeutics, and RNAi delivery.

Contacts:
James Hamilton MD, MBA
President


Jon Nagy PhD
Lead Scientist


Tim Trich MD, PhD
Chief Medical Officer

Copyright © NanoValent Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Spinning strands hint at folding dynamics: Rice University lab uses magnetic beads to model microscopic proteins, polymers October 17th, 2017

Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting(R) October 10th, 2017

Arrowhead to Present at Chardan Gene Therapy Conference October 3rd, 2017

'CRISPR-Gold' fixes Duchenne muscular dystrophy mutation in mice October 3rd, 2017

Announcements

A step closer to understanding quantum mechanics: Swansea Universityís physicists develop a new quantum simulation protocol October 22nd, 2017

Creation of coherent states in molecules by incoherent electrons October 21st, 2017

Strange but true: turning a material upside down can sometimes make it softer October 20th, 2017

Leti Coordinating Project to Develop Innovative Drivetrains for 3rd-generation Electric Vehicles: CEA Techís Contribution Includes Litenís Knowhow in Magnetic Materials and Simulation And Letiís Expertise in Wide-bandgap Semiconductors October 20th, 2017

Alliances/Trade associations/Partnerships/Distributorships

Leti Coordinating Project to Develop Innovative Drivetrains for 3rd-generation Electric Vehicles: CEA Techís Contribution Includes Litenís Knowhow in Magnetic Materials and Simulation And Letiís Expertise in Wide-bandgap Semiconductors October 20th, 2017

More 22 of 59,885 Print all In new window Leti to Present Update of CoolCube/3DVLSI Technologies Development at 2017 IEEE S3S: Future Developments and Tape-Out Vehicles to Be Presented during Oct. 17 Workshop October 12th, 2017

Quorum announces new customer support and demonstration facilities for users worldwide October 10th, 2017

GLOBALFOUNDRIES and Soitec Enter Into Long-term Supply Agreement on FD-SOI Wafers: Strategic milestone to help guarantee a secure, high-volume supply of FD-SOI technology September 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project